

# TRANSITION OF CARE (TOC) SUPPORT

For Patients, Caregivers, and Healthcare Providers

INSUPPORT® is here to provide information on the access process on behalf of people seeking treatment with PERSERIS® (risperidone) for extended-release injectable suspension. Patients transitioning to a new provider can receive assistance throughout the treatment journey. See below for additional details.



## Locate a Community Provider

Planning a transition of care for PERSERIS patients begins with identifying a provider or facility in the community that can continue their treatment. Available resources include, but are not limited to, the provider locator listed below.



To find a facility near you that can provide mental health treatment specific to your individual criteria (such as your type of insurance or preferred medication), you can visit the Behavioral Health Treatment Services Locator provided by the Substance Abuse and Mental Health Services Administration (SAMHSA).

Go to <https://findtreatment.samhsa.gov/>

When identifying a community provider, ensure the facility:



- Offers treatment with PERSERIS
- Accepts the patient's health insurance
- Is accepting new patients
- Can schedule an appointment by the next injection due date

INSUPPORT can help confirm that the provider selected meets these important requirements.

### WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. PERSERIS is not approved for the treatment of patients with dementia-related psychosis and has not been studied in this population.

## Request Support



INSUPPORT®'s TOC can provide important information to accommodate a successful transition process. INSUPPORT can help:

- Review insurance benefits
- Identify a facility that is able and willing to administer a PERSERIS injection
- Confirm that the patient's chosen community provider is able to see the patient by the patient's next injection due date

Enroll via the [INSUPPORT Patient Enrollment Form](#).

## Understand Next Steps After Selecting a Community Provider



Prior to changing healthcare settings, patients should obtain contact information for their new provider and learn their first appointment date and time, if scheduled. It is important for patients to know their next injection due date to maintain uninterrupted PERSERIS treatment.

## First Appointment Reminder



Appointment details can be sent through INSUPPORT's Patient Appointment Confirmation sheet.

## Begin Treatment With New Provider



Patients with private insurance can work with their new treatment provider to obtain information about how they may be able to lower their out-of-pocket cost for PERSERIS through enrollment in the INSUPPORT® Copay Assistance Program.\* Restrictions apply.



**As the patient continues treatment, INSUPPORT can support the patient and new provider with information on the access process for PERSERIS.**

For more information visit [www.INSUPPORT.com](http://www.INSUPPORT.com)  
or call INSUPPORT at **844-INSPPRT** (844-467-7778).

\*The Program benefit is valid for the out-of-pocket cost for PERSERIS only. It is not valid for any other out-of-pocket costs including costs associated with the administration of PERSERIS (for example, office visit or medication administration charges). Please see the Program [Terms and Conditions](#).

The INSUPPORT® Copay Assistance Program is valid ONLY for patients with private insurance who are prescribed PERSERIS for on-label use. Patients with government insurance are not eligible for the Copay Assistance Program, including, but not limited to, Medicare, Medicaid, Medigap, VA, DoD, TRICARE, CHAMPVA, or any other federally or state-funded government-assisted program. Other restrictions apply.

For **BOXED WARNING** refer to front page.

Please see accompanying full [Prescribing Information](#), including

**BOXED WARNING** or go to [PERSERISHCP.com](http://PERSERISHCP.com).

P-RAG-US-00441 EXPIRY September 2024

PERSERIS and INSUPPORT are registered trademarks of Indivior UK Limited.

© 2022 Indivior PLC | INDIVIOR is a registered trademark of Indivior UK Limited | All rights reserved.

inSupport



**PERSERIS®**

(risperidone) for extended-release  
90 mg · 120 mg injectable suspension